Targeting the ATR-CHK1 Axis in Cancer Therapy
AbstractTargeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented. View Full-Text
Share & Cite This Article
Rundle, S.; Bradbury, A.; Drew, Y.; Curtin, N.J. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers 2017, 9, 41.
Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers. 2017; 9(5):41.Chicago/Turabian Style
Rundle, Stuart; Bradbury, Alice; Drew, Yvette; Curtin, Nicola J. 2017. "Targeting the ATR-CHK1 Axis in Cancer Therapy." Cancers 9, no. 5: 41.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.